BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Cancers
Metastatic Cancer

Interventions: Drug: Cdc7-inhibitor

First Posted Date: 2009-04-23

Last Posted Date: 2023-04-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 11

Registration Number: NCT00886782

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇫🇷
Local Institution, Villejuif Cedex, France
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Advanced Cancer, Various, NOS

Interventions: Drug: BMS-833923
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2009-04-20

Last Posted Date: 2016-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 27

Registration Number: NCT00884546

Locations: 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

and more 4 locations

Safety Study to Evaluate BMS-830216 in Healthy Subjects

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BMS-830216
Drug: Placebo

First Posted Date: 2009-04-08

Last Posted Date: 2011-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 48

Registration Number: NCT00878020

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Phase 2

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Placebo
Drug: Daclatasvir
Drug: Peginterferon alpha-2a
Drug: ribavirin

First Posted Date: 2009-04-03

Last Posted Date: 2015-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 74

Registration Number: NCT00874770

Locations: 🇺🇸
Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸
Llc Dba The Research Institute, Springfield, Massachusetts, United States
🇺🇸
Veterans Affairs Medical Center, Bronx, New York, United States

and more 9 locations

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Phase 1

Withdrawn

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Dasatinib
Drug: Combination of Bendamustine + Dasatinib

First Posted Date: 2009-04-01

Last Posted Date: 2013-07-22

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00872976

Locations: 🇺🇸
Local Institution, Nashville, Tennessee, United States

Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: Ipilimumab

First Posted Date: 2009-03-13

Last Posted Date: 2016-09-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 988

Registration Number: NCT00861614

Locations: 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸
Arizona Clinical Research Center, Inc., Tucson, Arizona, United States
🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States

and more 43 locations

Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BMS-708163
Drug: BMS-708163 + Ketoconazole
Drug: Fluconazole
Drug: Ketoconazole
Drug: BMS-708163 + Fluconazole

First Posted Date: 2009-03-12

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT00860275

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

First Line Hepato Cellular Carcinoma (HCC)

Phase 3

Completed

Conditions: Hepato Cellular Carcinoma (HCC)

Interventions: Drug: Sorafenib
Drug: Brivanib
Drug: Placebo

First Posted Date: 2009-03-10

Last Posted Date: 2016-10-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1714

Registration Number: NCT00858871

Locations: 🇺🇸
Agajanian Institute Of Hematology And Oncology, Downey, California, United States
🇺🇸
Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States

and more 10 locations

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: BMS-790052

First Posted Date: 2009-03-10

Last Posted Date: 2015-10-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT00859053

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States

Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Paclitaxel

First Posted Date: 2009-03-04

Last Posted Date: 2010-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT00855764

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy